| Description | CMS-121, a quinolone derivative, is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage (EC50: 7 nM and 200 nM). CMS-121 shows strong neuroprotective, antioxidative, anti-inflammatory, and renoprotective activities. |
| In vitro | CMS-121 can increase acetyl-CoA in cells. CMS-121 (1 μM; 4 hours; HT22 cells) treatment also increases the phosphorylation of ACC1 at serine 79.[1]. |
| In vivo | CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. CMS-121 (~20 mg/kg; p.o; daily; for 4 months; female SAMP8 mice) treatment decreases cognitive decline and metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. [1]. |
| Synonyms | CMS121 |
| molecular weight | 321.37 |
| Molecular formula | C20H19NO3 |
| CAS | 1353224-53-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (171.14 mM), Sonication is recommended. |
| References | 1. Currais A, et al. Elevating acetyl-CoA levels reduces aspects of brain aging. Elife. 2019 Nov 19;8. pii: e47866. 2. Chiruta C, et al. Chemical modification of the multitarget neuroprotective compound fisetin. J Med Chem. 2012 Jan 12;55(1):378-89. 3. Prior M, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014 Jul 16;5(7):503-13. |